Porphyria (Erythropoietic Protoporphyri) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Porphyria (Erythropoietic Protoporphyri) – Drugs In Development, 2024 report and make more profitable business decisions.
Erythropoietic protoporphyria (EPP) is an inherited porphyria caused by the accumulation of protoporphyrins in red blood cells that causes acute, painful photosensitivity and potential liver disease. It usually occurs in early childhood with immediate pain and crying upon exposure to bright sunlight. It is a lifelong disease, and repeated phototoxic reactions eventually lead to thickening of the skin and wax-like scarring on the face.
The Porphyria (Erythropoietic Protoporphyri) drugs in development market research report provide comprehensive information on the therapeutics under development for Porphyria (Erythropoietic Protoporphyri), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Porphyria (Erythropoietic Protoporphyri) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Porphyria (Erythropoietic Protoporphyri) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 9 molecules, with 8 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Porphyria (Erythropoietic Protoporphyri) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Porphyria (Erythropoietic Protoporphyri) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Porphyria (Erythropoietic Protoporphyri) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ATLAS Molecular Pharma SLClinuvel Pharmaceuticals Ltd
Disc Medicine Inc
Mitsubishi Tanabe Pharma Corp
Moderna Inc
Ractigen Therapeutics Inc
Recordati SpA
University of Navarra
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Porphyria (Erythropoietic Protoporphyri) reports